top of page

This site was designed with the

website builder. Create your website today.Start Now

Advancing the Management of Urothelial Cancer With Immuno-Oncology and Targeted Approaches

Dr. Ayman Nashashibi, MD
Jun 22, 2019
1 min read

Describe the rationale for the FDA revised indication for both atezolizumab and pembrolizumab in cisplatin-ineligible patients with advanced rrothelial carcinoma

Recent Posts

Unraveling the Complex Treatment Landscape of Prostate Cancer

Unraveling the Complex Treatment Landscape of Prostate Cancer

Keeping Pace With Immunotherapy Advances in Bladder Cancer

Keeping Pace With Immunotherapy Advances in Bladder Cancer

Unravel the complexities of prostate cancer management

Unravel the complexities of prostate cancer management

Comments

bottom of page